Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic LeukemiaA Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsPhase 2 Study of Carfilzomib in Relapsed and Refractory Multiple MyelomaVelcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneA Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's LymphomaA Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaDasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsVaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's LymphomaAlternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic SyndromesVaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaGefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast CancerA Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialMK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyMK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous TherapyAkt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
P6153
Q61914917-B9D16708-B1DE-4EE2-9828-637CF370C568Q61918466-365BEA0E-3A0A-4F43-B0B2-2E5EA9F5A78DQ61932780-ACFA09E1-8765-4CB6-88A8-514DB2F95168Q61979131-82423D95-A3ED-4C90-AFF0-CFFF145E2159Q61979804-8E47E441-BA9C-427B-83D2-7B4B5D333371Q61980997-7DAD7748-CE5D-4972-9B25-9F80F83102D3Q61981180-39E1690B-786E-4FBF-8107-159ADF0E5A75Q61981563-0B38FBA8-63EA-422B-BB6C-D8E122F1180DQ62105834-6F9ABD16-5213-47F9-A71E-205A78F2B8B1Q62106212-9023BBF8-DA2A-4580-B1E1-F6E48BFDCB43Q62110090-8E17BEFD-21C0-4A78-9F7B-9E1C1F6618A2Q62110456-2046F9B2-A50D-4804-84E0-8004EA3E4E09Q63063190-2A0C20F7-F8F1-43DA-B152-C3000F27B931Q63339406-CA7BF97E-B2F8-420F-AA38-D93E8C1652A9Q63340391-C3F97588-7016-4864-BA9E-4F8FB1FF8FFBQ63340393-8E804B07-B6FA-4CD5-AB07-44CC2B4C1850
P6153
description
americká firma
@cs
amerikanische Non-Profit-Organisation
@de
non-profit organisation in the USA
@en
name
Tower Cancer Research Foundation
@en
Tower Cancer Research Foundation
@fr
type
label
Tower Cancer Research Foundation
@en
Tower Cancer Research Foundation
@fr
prefLabel
Tower Cancer Research Foundation
@en
Tower Cancer Research Foundation
@fr
P3153
P6366
P1297
95-4596354
P159
P2139
P2427
grid.478023.a
P3153
P4861
P571
1996-01-01T00:00:00Z